We spend more than a decade training physicians and teach them almost nothing about leading people. So, what do we do? We take the best clinician in the group, hand them the title, and assume that leadership comes with it. The post Follow the Leader: How to Build and Retain Great Clinical Teams appeared first…
Oura will be integrating Counsel Health’s clinical AI and virtual care into its app, but will payers and employers cover the Oura ring as a benefit? And will consumers sign on to pay a much more expensive monthly subscription for AI-enabled medical insights and access to licensed physicians? The post Oura’s Buys Counsel for $625M,…
Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class cardiovascular medicines Approval of the once-daily pill covers secondary stroke prevention in adults. The post FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke appeared first on MedCity News.
Healthcare has plenty of tedious administrative work which could benefit from AI’s efficiency – but what if simply speeding up an already broken system isn’t the answer? Healthcare leaders push for a re-built, AI-native system in Anterior’s recent Beyond Faster Horses campaign. The post New Campaign Wants AI Applications To Look Beyond Speed appeared first…
The industry’s next major competitor may never build another national laboratory network or employ thousands of phlebotomists. It may simply own the device that notices something first. The post The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist appeared first on MedCity News.
Avanlee Care’s seed round was led by BEA Venture Fund, with participation from existing investors, including Board Chair Esther Dyson, Chrysalis Ventures and FairBridge VC. The post Startup Supporting Caregivers Raises $3.5M in Seed Funding appeared first on MedCity News.
In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now. The post Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health” appeared…
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies. The post Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition appeared first on MedCity News.
Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear methodological standards, and without crushing noncommercial research, could make trials safer, faster, cheaper, and more reliable, without sacrificing rigor….
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that reset the immune system to treat autoimmune disease. The post Nkarta Autoimmune…